[{"id":"8357d385-35ac-4d87-9fa3-47078a947c30","acronym":"","url":"https://clinicaltrials.gov/study/NCT02650986","created_at":"2021-01-18T12:54:24.654Z","updated_at":"2024-07-02T16:34:26.492Z","phase":"Phase 1/2","brief_title":"Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1","source_id_and_acronym":"NCT02650986","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" BRAF • CTAG1B","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • cyclophosphamide • decitabine • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 07/14/2017","start_date":" 07/14/2017","primary_txt":" Primary completion: 03/04/2021","primary_completion_date":" 03/04/2021","study_txt":" Completion: 07/14/2032","study_completion_date":" 07/14/2032","last_update_posted":"2024-06-13"},{"id":"2c844ff3-38e3-4e1a-ab45-51650b975490","acronym":"","url":"https://clinicaltrials.gov/study/NCT05848739","created_at":"2023-05-08T15:04:02.971Z","updated_at":"2024-07-02T16:34:38.208Z","phase":"Phase 1","brief_title":"A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors","source_id_and_acronym":"NCT05848739","lead_sponsor":"Sapience Therapeutics","biomarkers":" PD-L1 • MSI • BRCA","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR • BRCA mutation","tags":["PD-L1 • MSI • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • Fruzaqla (fruquintinib) • leucovorin calcium • ST316"],"overall_status":"Recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 06/05/2023","start_date":" 06/05/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2024-06-05"},{"id":"89a914ac-06d5-4cf1-bba9-6ccd8e3df332","acronym":"","url":"https://clinicaltrials.gov/study/NCT06083883","created_at":"2023-10-16T16:13:47.307Z","updated_at":"2024-07-02T16:34:59.004Z","phase":"Phase 1","brief_title":"Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1","source_id_and_acronym":"NCT06083883","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-A • CTAG1B • SSX1","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A • CTAG1B • SSX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 03/27/2024","start_date":" 03/27/2024","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2028","study_completion_date":" 11/30/2028","last_update_posted":"2024-06-04"},{"id":"a5409d19-a682-484b-8074-dbc0380cdead","acronym":"","url":"https://clinicaltrials.gov/study/NCT02601950","created_at":"2021-01-17T17:38:36.460Z","updated_at":"2024-07-02T16:35:07.229Z","phase":"Phase 2","brief_title":"A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma","source_id_and_acronym":"NCT02601950","lead_sponsor":"Epizyme, Inc.","biomarkers":" CD34 • SS18","pipe":" | ","alterations":" SMARCA4 mutation","tags":["CD34 • SS18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat)"],"overall_status":"Completed","enrollment":" Enrollment 267","initiation":"Initiation: 12/22/2015","start_date":" 12/22/2015","primary_txt":" Primary completion: 02/26/2024","primary_completion_date":" 02/26/2024","study_txt":" Completion: 02/26/2024","study_completion_date":" 02/26/2024","last_update_posted":"2024-04-29"},{"id":"81497553-3d5a-49ef-8513-cf9cb5b29947","acronym":"","url":"https://clinicaltrials.gov/study/NCT05642455","created_at":"2022-12-08T14:57:33.766Z","updated_at":"2024-07-02T16:35:07.743Z","phase":"Phase 1/2","brief_title":"SPEARHEAD-3 Pediatric Study","source_id_and_acronym":"NCT05642455","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • HLA-A2 positive • MAGEA4 expression","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A2 positive • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecelra (afamitresgene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 07/30/2038","study_completion_date":" 07/30/2038","last_update_posted":"2024-04-24"},{"id":"84a8bbc2-ef05-45fb-8d2a-c2429e123035","acronym":"STRIvE-02","url":"https://clinicaltrials.gov/study/NCT04483778","created_at":"2021-01-18T21:31:43.742Z","updated_at":"2024-07-02T16:35:07.947Z","phase":"Phase 1","brief_title":"B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults","source_id_and_acronym":"NCT04483778 - STRIvE-02","lead_sponsor":"Seattle Children's Hospital","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression • CD19 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SCRI-CARB7H3(s) • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2040","study_completion_date":" 12/01/2040","last_update_posted":"2024-04-23"},{"id":"e1485158-d730-462d-be42-9cd0f137d814","acronym":"STRIvE-01","url":"https://clinicaltrials.gov/study/NCT03618381","created_at":"2021-01-18T17:46:54.866Z","updated_at":"2024-07-02T16:35:10.845Z","phase":"Phase 1","brief_title":"EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults","source_id_and_acronym":"NCT03618381 - STRIvE-01","lead_sponsor":"Seattle Children's Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR806-specific CAR T-cell therapy • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 06/18/2019","start_date":" 06/18/2019","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2040","study_completion_date":" 06/01/2040","last_update_posted":"2024-04-09"},{"id":"2c13cc26-0e5f-458f-80db-772216b113f8","acronym":"SPEARHEAD-1","url":"https://clinicaltrials.gov/study/NCT04044768","created_at":"2021-01-18T19:50:39.967Z","updated_at":"2024-07-02T16:35:18.934Z","phase":"Phase 2","brief_title":"Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma","source_id_and_acronym":"NCT04044768 - SPEARHEAD-1","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • MAGEA4 expression","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecelra (afamitresgene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/13/2019","start_date":" 08/13/2019","primary_txt":" Primary completion: 10/10/2021","primary_completion_date":" 10/10/2021","study_txt":" Completion: 04/01/2038","study_completion_date":" 04/01/2038","last_update_posted":"2024-02-19"},{"id":"74ab63fa-a275-4c6e-8d0a-d4cf89008c47","acronym":"","url":"https://clinicaltrials.gov/study/NCT04995003","created_at":"2021-08-06T12:53:09.619Z","updated_at":"2024-07-02T16:35:22.177Z","phase":"Phase 1","brief_title":"HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma","source_id_and_acronym":"NCT04995003","lead_sponsor":"Baylor College of Medicine","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 12/07/2021","start_date":" 12/07/2021","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2040","study_completion_date":" 12/31/2040","last_update_posted":"2024-01-25"},{"id":"4317ceb2-4fba-4c3e-9e3a-12523bffaa99","acronym":"","url":"https://clinicaltrials.gov/study/NCT03132922","created_at":"2021-01-18T15:26:11.009Z","updated_at":"2024-07-02T16:35:22.736Z","phase":"Phase 1","brief_title":"MAGE-A4ᶜ¹º³²T for Multi-Tumor","source_id_and_acronym":"NCT03132922","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • HLA-A2 positive","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecelra (afamitresgene autoleucel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 05/15/2017","start_date":" 05/15/2017","primary_txt":" Primary completion: 12/27/2022","primary_completion_date":" 12/27/2022","study_txt":" Completion: 09/01/2032","study_completion_date":" 09/01/2032","last_update_posted":"2024-01-22"},{"id":"c57ea625-cd33-4c56-acff-cfd618294813","acronym":"","url":"https://clinicaltrials.gov/study/NCT05492682","created_at":"2022-08-08T11:56:49.629Z","updated_at":"2024-07-02T16:35:23.644Z","phase":"Phase 1","brief_title":"START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer","source_id_and_acronym":"NCT05492682","lead_sponsor":"Valo Therapeutics Oy","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • PeptiCRAd-1"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/02/2023","start_date":" 02/02/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-01-12"},{"id":"96478ee8-ea1d-46f0-9076-86b0a0a5b146","acronym":"","url":"https://clinicaltrials.gov/study/NCT02869217","created_at":"2021-02-16T02:53:03.033Z","updated_at":"2024-07-02T16:35:26.728Z","phase":"Phase 1","brief_title":"Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors","source_id_and_acronym":"NCT02869217","lead_sponsor":"University Health Network, Toronto","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02 • CTAG1B expression","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • mipetresgene autoleucel (TBI-1301) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-12-08"},{"id":"2af4501d-3698-4fa1-bef4-a73d1a7b2ae3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03250325","created_at":"2021-02-16T02:53:12.531Z","updated_at":"2024-07-02T16:35:26.928Z","phase":"Phase 1/2","brief_title":"Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma","source_id_and_acronym":"NCT03250325","lead_sponsor":"Takara Bio Inc.","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02 • CTAG1B expression","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • mipetresgene autoleucel (TBI-1301) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 09/20/2017","start_date":" 09/20/2017","primary_txt":" Primary completion: 01/23/2020","primary_completion_date":" 01/23/2020","study_txt":" Completion: 03/09/2022","study_completion_date":" 03/09/2022","last_update_posted":"2023-12-06"},{"id":"178a1cb1-a173-4995-8639-0efd4bf3c999","acronym":"PerVision","url":"https://clinicaltrials.gov/study/NCT06094101","created_at":"2023-10-23T19:13:33.085Z","updated_at":"2024-07-02T16:35:28.264Z","phase":"Phase 1/2","brief_title":"Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)","source_id_and_acronym":"NCT06094101 - PerVision","lead_sponsor":"University Hospital Tuebingen","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/19/2023","start_date":" 09/19/2023","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2023-11-22"},{"id":"0ed959af-c2b5-458e-b542-28311d0168e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03063632","created_at":"2021-01-18T15:05:12.923Z","updated_at":"2024-07-02T16:35:31.715Z","phase":"Phase 2","brief_title":"Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma","source_id_and_acronym":"NCT03063632","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNG • CTAG1B","pipe":" | ","alterations":" CTAG1B expression","tags":["IFNG • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Actimmune (interferon gamma-1 b) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 12/14/2017","start_date":" 12/14/2017","primary_txt":" Primary completion: 04/08/2021","primary_completion_date":" 04/08/2021","study_txt":" Completion: 03/14/2023","study_completion_date":" 03/14/2023","last_update_posted":"2023-10-25"},{"id":"02699193-e287-431a-b255-1adc890318f2","acronym":"NCI-2018-00926","url":"https://clinicaltrials.gov/study/NCT03450122","created_at":"2021-01-19T15:37:56.641Z","updated_at":"2024-07-02T16:35:33.518Z","phase":"Phase 1","brief_title":"Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma","source_id_and_acronym":"NCT03450122 - NCI-2018-00926","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-A • CTAG1B","pipe":"","alterations":" ","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Proleukin (aldesleukin) • CMB305 • ID-LV305 • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 09/13/2018","start_date":" 09/13/2018","primary_txt":" Primary completion: 12/06/2022","primary_completion_date":" 12/06/2022","study_txt":" Completion: 12/06/2022","study_completion_date":" 12/06/2022","last_update_posted":"2023-10-16"},{"id":"cf75cef8-fbca-4f5e-981f-7832552ff034","acronym":"","url":"https://clinicaltrials.gov/study/NCT05993299","created_at":"2023-08-15T19:10:23.528Z","updated_at":"2024-07-02T16:35:33.510Z","phase":"Phase 2","brief_title":"Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma","source_id_and_acronym":"NCT05993299","lead_sponsor":"GlaxoSmithKline","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 12/31/2019","start_date":" 12/31/2019","primary_txt":" Primary completion: 10/12/2022","primary_completion_date":" 10/12/2022","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-10-16"},{"id":"640b8ea4-dbbe-4ef7-aaf3-6fff167a55c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03009201","created_at":"2021-01-18T14:48:19.930Z","updated_at":"2024-07-02T16:35:39.919Z","phase":"Phase 1b","brief_title":"Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT03009201","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" RB1","pipe":"","alterations":" ","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Kisqali (ribociclib)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 03/10/2017","start_date":" 03/10/2017","primary_txt":" Primary completion: 10/08/2019","primary_completion_date":" 10/08/2019","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2023-08-16"},{"id":"ea505106-f0f3-438c-81cb-5a4b65a69585","acronym":"","url":"https://clinicaltrials.gov/study/NCT02452554","created_at":"2021-01-18T11:45:46.897Z","updated_at":"2024-07-02T16:36:18.487Z","phase":"Phase 2","brief_title":"Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma","source_id_and_acronym":"NCT02452554","lead_sponsor":"Children's Oncology Group","biomarkers":" NCAM1","pipe":" | ","alterations":" NCAM1 expression","tags":["NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NCAM1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lorvotuzumab mertansine (IMGN901)"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 10/12/2015","start_date":" 10/12/2015","primary_txt":" Primary completion: 06/30/2017","primary_completion_date":" 06/30/2017","study_txt":" Completion: 09/30/2021","study_completion_date":" 09/30/2021","last_update_posted":"2022-01-13"},{"id":"ec4f91aa-0ba7-45c0-9101-b6c7390334c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02601937","created_at":"2021-01-17T17:40:42.252Z","updated_at":"2024-07-02T16:36:19.156Z","phase":"Phase 1","brief_title":"A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma","source_id_and_acronym":"NCT02601937","lead_sponsor":"Epizyme, Inc.","biomarkers":" SS18","pipe":" | ","alterations":" SMARCA4 mutation","tags":["SS18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat)"],"overall_status":"Completed","enrollment":" Enrollment 109","initiation":"Initiation: 01/07/2016","start_date":" 01/07/2016","primary_txt":" Primary completion: 10/22/2021","primary_completion_date":" 10/22/2021","study_txt":" Completion: 10/22/2021","study_completion_date":" 10/22/2021","last_update_posted":"2021-12-27"},{"id":"371e00b7-13f0-4e7a-9ae5-dfcb18a5df87","acronym":"ADP 04511","url":"https://clinicaltrials.gov/study/NCT01343043","created_at":"2021-02-16T02:52:18.139Z","updated_at":"2024-07-02T16:36:28.459Z","phase":"Phase 1","brief_title":"A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma","source_id_and_acronym":"NCT01343043 - ADP 04511","lead_sponsor":"GlaxoSmithKline","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02 • CTAG1B expression","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 09/27/2012","start_date":" 09/27/2012","primary_txt":" Primary completion: 06/18/2019","primary_completion_date":" 06/18/2019","study_txt":" Completion: 06/18/2019","study_completion_date":" 06/18/2019","last_update_posted":"2021-06-30"},{"id":"031439da-5f9c-460c-8c05-2a1c5a400206","acronym":"","url":"https://clinicaltrials.gov/study/NCT03638206","created_at":"2021-01-18T17:51:53.397Z","updated_at":"2024-07-02T16:36:52.614Z","phase":"Phase 1/2","brief_title":"Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies","source_id_and_acronym":"NCT03638206","lead_sponsor":"Shenzhen BinDeBio Ltd.","biomarkers":" MET • CD19 • HLA-A • MSLN • CD22 • CD33 • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • CD19 expression • HLA-A positive","tags":["MET • CD19 • HLA-A • MSLN • CD22 • CD33 • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • CD19 expression • HLA-A positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CAR-T cell immunotherapy • multi-target gene-modified CAR-T/TCR-T cell immunotherapy"],"overall_status":"Recruiting","enrollment":" Enrollment 73","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2019-12-11"},{"id":"1e974883-8eac-41fa-b002-5587e91aec89","acronym":"","url":"https://clinicaltrials.gov/study/NCT00004853","created_at":"2021-01-17T22:56:18.874Z","updated_at":"2024-07-02T16:36:53.833Z","phase":"Phase 1","brief_title":"Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy","source_id_and_acronym":"NCT00004853","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD34","pipe":" | ","alterations":" CD34 positive","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD34 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 03/03/2000","start_date":" 03/03/2000","primary_txt":" Primary completion: 05/20/2009","primary_completion_date":" 05/20/2009","study_txt":" Completion: 05/20/2009","study_completion_date":" 05/20/2009","last_update_posted":"2019-11-12"},{"id":"837e1307-aff9-47a1-8cb7-f58eedd670f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03697824","created_at":"2021-01-18T18:07:24.635Z","updated_at":"2024-07-02T16:36:54.161Z","phase":"Phase 1b/2a","brief_title":"Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a","source_id_and_acronym":"NCT03697824","lead_sponsor":"GlaxoSmithKline","biomarkers":" HLA-A • CTAG1B • CTAG2","pipe":" | ","alterations":" HLA-A*02 • CTAG2 expression","tags":["HLA-A • CTAG1B • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • CTAG2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794) • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/25/2019","start_date":" 02/25/2019","primary_txt":" Primary completion: 07/18/2022","primary_completion_date":" 07/18/2022","study_txt":" Completion: 07/18/2022","study_completion_date":" 07/18/2022","last_update_posted":"2019-10-29"}]